XLV Outperforms XBI in Affordability and Dividend Yields

The State Street Health Care Select Sector SPDR ETF (XLV) and the State Street SPDR S&P Biotech ETF (XBI) are two popular healthcare-focused exchange-traded funds. The XLV offers broad exposure to established healthcare giants at a minimal cost, while XBI provides a more volatile focus on biotechnology sub-sectors.

With an expense ratio of 0.08%, XLV is notably more affordable than XBI's 0.35% fee. This cost difference also translates into higher dividend yields for XLV investors, with a trailing-12-month distribution yield of 1.6% compared to XBI's 0.4%.

XLV tracks 60 large-cap stocks within the Health Care Select Sector Index, offering exposure to pharmaceuticals, medical equipment, and healthcare providers. On the other hand, XBI follows a modified equal-weight strategy across 155 biotechnology stocks, reducing the influence of individual giants in favor of broader industry participation.

While XBI's high-risk focus has delivered tremendous returns over the past year, its volatility makes it one of the most unpredictable ways to own healthcare. For long-term investors seeking a dependable healthcare foundation, XLV is often considered a more suitable choice for its defensive characteristics and lower price point.